Apogee files to go pub­lic, un­veil­ing plans to make a play for Dupix­en­t's turf

Apogee Ther­a­peu­tics launched last year with $169 mil­lion in pri­vate fi­nanc­ing and is head­ed for an IPO.

The start­up was spun out of Paragon Ther­a­peu­tics in De­cem­ber but with few de­tails about ex­act­ly what tar­gets it would go af­ter. Thurs­day’s IPO fil­ing pro­vides some de­tails.

Its drug APG777 is an un­der-the-skin mAb tar­get­ing IL-13 and will en­ter a healthy vol­un­teer study in Aus­tralia in the sec­ond half of this year. If the da­ta are pos­i­tive, it will go in­to a Phase II tri­al in atopic der­mati­tis. It al­so has APG808, a mAb tar­get­ing IL-4Rα for COPD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER